Passa al contenuto
Merck
  • Patient-specific genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome.

Patient-specific genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome.

eLife (2020-10-03)
Jeanne L Theis, Georg Vogler, Maria A Missinato, Xing Li, Tanja Nielsen, Xin-Xin I Zeng, Almudena Martinez-Fernandez, Stanley M Walls, Anaïs Kervadec, James N Kezos, Katja Birker, Jared M Evans, Megan M O'Byrne, Zachary C Fogarty, André Terzic, Paul Grossfeld, Karen Ocorr, Timothy J Nelson, Timothy M Olson, Alexandre R Colas, Rolf Bodmer
ABSTRACT

Congenital heart diseases (CHDs), including hypoplastic left heart syndrome (HLHS), are genetically complex and poorly understood. Here, a multidisciplinary platform was established to functionally evaluate novel CHD gene candidates, based on whole-genome and iPSC RNA sequencing of a HLHS family-trio. Filtering for rare variants and altered expression in proband iPSCs prioritized 10 candidates. siRNA/RNAi-mediated knockdown in healthy human iPSC-derived cardiomyocytes (hiPSC-CM) and in developing Drosophila and zebrafish hearts revealed that LDL receptor-related protein LRP2 is required for cardiomyocyte proliferation and differentiation. Consistent with hypoplastic heart defects, compared to patents the proband's iPSC-CMs exhibited reduced proliferation. Interestingly, rare, predicted-damaging LRP2 variants were enriched in a HLHS cohort; however, understanding their contribution to HLHS requires further investigation. Collectively, we have established a multi-species high-throughput platform to rapidly evaluate candidate genes and their interactions during heart development, which are crucial first steps toward deciphering oligogenic underpinnings of CHDs, including hypoplastic left hearts.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Monoclonal Anti-α-Actinin (Sarcomeric) antibody produced in mouse, clone EA-53, ascites fluid
Sigma-Aldrich
BIO, ≥98% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human TP53
Sigma-Aldrich
MISSION® esiRNA, targeting human SDHD
Sigma-Aldrich
MISSION® esiRNA, targeting human APOB
Sigma-Aldrich
MISSION® esiRNA, targeting human SIK1, CH507-42P11.8
Sigma-Aldrich
MISSION® esiRNA, targeting human PRTG
Sigma-Aldrich
MISSION® esiRNA, targeting human ELF4
Sigma-Aldrich
MISSION® esiRNA, targeting human PTCH1
Sigma-Aldrich
MISSION® esiRNA, targeting human HS6ST2
Sigma-Aldrich
MISSION® esiRNA, targeting human HSPG2
Sigma-Aldrich
MISSION® esiRNA, targeting human LRP2